Journal articles: 'Psorisis' – Grafiati (2025)

Abstract:

Psoriasis is an immune disorder disease which has genetic cause. It is benign disease, and usually lies in dormant status in the body until the patient triggered by a variety of factors such as environment, lifestyle and diet. The disease has an effect on the aesthetic, many serious complications and affects a large number of the world population. Until now, there are no specific method of cure only treatment of disease stabilization, avoidance complications and improvement quality of life for patients. Genetic studies of psoriasis have been identified 13 loci associated to susceptibility of disease. Among them, the PSORS1 region on chromosome 6p21.3 was identified as highest relevant to susceptibility of disease. In this study, blood samples of the Vietnamese patients with psoriasis disease were collected and investigated. Exons in PSORS1C3 gene, one gene in locus PSORS1, in psoriasis patients were amplified by using specific primer pairs. The single nucleotide polymorphisms (SNP) of PSORS1C3 gene were determined by sequencing and comparing with the reference sequence in Ensembl. We found out 14 SNPs including of 6 SNPs rs3868542, rs11507945, rs11507946, rs3871247, rs11507947, rs3871246 on exon 1; 2 SNPs rs3099189, rs3132517 on exon 2; 6 SNPs rs887467, rs887468, rs1061503, rs2269711, rs11507948 and rs11507949 on exon 3 of PSORS1C3 gene in Vietnamese patients with psorisis disease. The results showed that there was one SNP rs3871246 have significant association to susceptibility of disease with p

Abstract:

To evaluate the role of psoriasin, koebnerisin, interleukn (IL)-12 and IL-23 in the pathogenesis of psoriasis and their relations to Psoriasis Area Severity Index (PASI) and obesity. Thirty patients had chronic plaque psoriasis and 30 healthy subjects matched in age and sex were enrolled in this study. Serum from all subjects were used for determination of psoriasin, koebnerisin, IL-12 and IL-23 by ELISA kits. IL-23 and psoriasin were significantly higher in skin psoriasis compared to controls and psoriatic arthritis (PsA). There was a correlation between psoriasin and both PASI and obesity. On the other hand, IL-12 was significantly increased in PsA compared to skin psoriasis (p= 0.000) and controls. Its sensitivity and specificity were 87%, 93%; respectively. To our knowledge, psoriasin is the first biomarker confirm the link between obesity and psoriasis. The risk of developing psoriasis is directly related to higher BMI.

Abstract:

Psoriasis is a chronic skin disease in which genetics play a major role. Although many genome-wide association studies have been performed in psoriasis, knowledge of the age at onset remains limited. Therefore, we analyzed 173 single-nucleotide polymorphisms in genes associated with psoriasis and other autoimmune diseases in patients with moderate-to-severe plaque psoriasis type I (early-onset, <40 years) or type II (late-onset, ≥40 years) and healthy controls. Moreover, we performed a comparison between patients with type I psoriasis and patients with type II psoriasis. Our comparison of a stratified population with type I psoriasisn=155and healthy controlsN=197is the first to reveal a relationship between theCLMN,FBXL19,CCL4L,C17orf51,TYK2,IL13,SLC22A4,CDKAL1, andHLA-B/MICAgenes. When we compared type I psoriasis with type II psoriasisN=36, we found a significant association between age at onset and the genesPSORS6,TNF-α,FCGR2A,TNFR1,CD226,HLA-C,TNFAIP3, andCCHCR1. Moreover, we replicated the association between rs12191877 (HLA-C) and type I psoriasis and between type I and type II psoriasis. Our findings highlight the role of genetics in age of onset of psoriasis.

Abstract:

To improve the management of psoriasis, we have started from the hypothesis that normalization of vitamin D serum reduces the severity of psoriasis and positively influences the diagnostic criteria of metabolic syndrome. Experimental part. The objective of the prospective study was to evaluate the impact of oral vitamin D on psoriazis and metabolic syndrome in a group of 184 patients diagnosed with psoriazis and metabolic syndrome, between 2010-2017. In all patients included in the study, we evaluated family history, personal medical history, the living and working conditions, the history of psoriatic disease (control group only), clinical data (waist circumference), height (cm), body mass index, blood pressure (mmHg)) and laboratory examinations. Regarding the severity of psoriasis, in all 141 patients treated with vitamin D, a significant improvement was seen after 12 months of treatment. We bring a new approach to the treatment of psoriasis with vitamin D.

Abstract:

<p>Psoriasis is a skin disorder characterized by skin inflammation and plaques. Induction of psoriasis in animal model include following steps: a) Selection of animal model, b) Hair removing from the back or ear, c) treatment of skin with Aldara, a cream containing 5% imiquimod and d) Observation. Imiquimod-induced skin inflammation in animal model resembles with psoriasis.</p><p><strong>Video Clip:</strong></p><p><a href="https://youtube.com/v/QY-RESHbH-U">Psoriaisis-like skin:</a> 9 min 10 sec</p>

Abstract:

Study Objective: to present literature review of clinical parameters and course of psoriatic arthritis (PsA) in children, and results of PsA patients examination in University Clinical Children Hospital of I.M. Sechenov First Moscow State Medical University. Study Design: open prospective study. Materials and Methods. We analysed medical records of 83 children with PsA aged 3 to 17 years who were examined and managed in University Clinical Children Hospital of I.M. Sechenov First Moscow State Medical University in 1989 – 2019. Study Results. Confirmed PsA was diagnosed in 59 (71%) children, suspected PsA — in 24 (29%) children; 44 (53%) children got ill before they were 6.5 years old. In 24 (29%) patients, disease started with skin involvement; in 59 (71%) patients, articular syndrome was the first manifestation of disease. In the group of patients with confirmed psoriasis, the most common was plaque psoriasis: it was diagnosed in 45 (76.3%) out of 59 children; guttate psoriasis was found in 8 (13.5%) children, isolated nail plaque psoriasis — in 3 (5.1%) patients, and palm and foot psoriasis — in 3 (5.1%) children. Psoriasis of the scalp was diagnosed in 23 (39%) subjects. In 8 (13.5%) patients, skin syndrome was associated with mild infiltration and scant desquamation. 18 (21.7%) out of 83 children had skin involvement together with nail bed involvement. Psoriasic onychodystrophy was diagnosed in 19 (23%) children (onycholysis, “oil patches” on fingers and toes); 15 (18.1%) children had “thimble syndrome”. On disease onset, 68.7% of children had oligoarticular, sometimes asymmetric articular syndrome; 18.1% had symmetric rheumatoid-like disease, 13.2% — psoriasic spondylitis. After 5 years of follow-up, articular syndrome transformed: 41.2% of patients had symmetric rheumatoid-like disease, 24.1% — asymmetric oligoarthritis, 24.1% — spondylarthritis with peripheral joint involvement, and 10.8% — arthritis mutilans. Most commonly PsA affected knee, talocrural joints, small hand joints – 41%, 31.3%, 29%, respectively. Conclusion. Clinical manifestations of PsA varied a lot. Our patients did not have a second peak. Almost one third of children had skin changes prior to arthritis development. Onset of disease was associated with asymmetric oligoarthritis prevalence. Later, articular syndrome changed, and symmetric rheumatoid-like disease prevailed. Keywords: children, psoriatic arthritis, psoriasis, juvenile idiopathic arthritis, Vancouver diagnostic criteria.

Abstract:

- Psoriasis is one of the prevalent skin diseases in the World. This chronic condition has a significant negative impact on patients' quality of life (QoL). The Skindex-29 is a selfadministered questionnaire assessing QoL of patients with skin diseases in 3 domains: burden of symptoms, social functioning, and emotional responses. Recently, authors (Nijsten et al., 2006) have developed a short version made up by 17 item that measures two dimensions: burden of symptoms and psychosocial responses. The aim of present study was to examine the psychometric properties of the both versions: original (Skindex-29) and short version (Skindex-17). Confirmatory factor analyses, conducted on a group of 360 psoriasis patients, supported the construct validity of the Skindex-17. Adequate internal consistency and significant distress correlations were found. Overall results suggested that Skindex-17 represented a brief and easily administrable questionnaire as well as a useful tool for both clinicians and researchers interested to assess QoL of psoriasis patients.Key words: psoriasis, quality of life, measurement, skindex, confirmative analysesParole chiave: psoriasi, qualitŕ di vita, misura, skindex, analisi confermative

Abstract:

Psoriasis is a residual chronic inflammatory skin disease, characterized by a predominance of pustular eruptions accompanied by systemic symptoms such as fever lasting several days. . Psoriasis in pregnancy can lead to spontaneous abortion, stillbirth and preterm birth. Reported the case of Mrs. YS 38 years old, received from the genital skin section of RS M Djamil Padang with a diagnosis of G3P2A0H2 + pustular psoriasis. Fetomaternal ultrasound was performed, obtained biometrics: BPD: 80mm, FL: 61 mm, HL: 54 mm, AC 271 mm, AFI 10.7 cm, SDAU 2.79, estimated fetal weight 1700-1800 grams. Impression: gravid 31-32 weeks, single live fetus intra uterine. Patients are planned for administration of high doses of corticosteroids. Informed consent to the patient and family about the actions to be performed. Corticosteroid was administered as much as 30 mg long term with a dose of prednisone in tappering off every 2 weeks. The patient was discharged for control to the skin clinic and obstetrics, the patient came 12 days later and was consulted to the obstetrics department for termination of the pregnancy but from the obstetrics department there was no confirmation for termination of the pregnancy. The patient then came 13 days later with 18 hours PRM. Pregnancy termination by cesarean section was performed. a baby girl was born with LBW: 3000 gr, PB: 48 cm, A / S: 8/9, there were no congenital abnormalities such as growth disorders, cleft lip, cataracts, and polycystic kidney disease in infants. The cause of psoriasis in this case is probably pregnancy.Keywords: pustularis psoriais, psoriasis, pregnancy, corticosteroid

Abstract:

Aims: The nail unit is a matter of interest both for dermatologist and rheumatologist. The nail is considered one of the possible targets of assessment, especially when ultrasonography is performed. The aim of the study is to highlight peculiar features and alterations of the nail unit in patients affected by psoriasis and psoriatic arthritis versus healthy controls using ultrasonography.Materials and methods: The study sample included 82 patients affected by psoriasis and/or psoriatic arthritis and 50 healthy controls. The patients were consecutively enrolled during their routine visit in the outpatient clinic and they performed clinical and ultrasonographic evaluation of the nail. The evaluationof disease activity was done using Disease Activity in Psoriatic Arthritis (DAPSA), Psoriasis Activity Severity Index (PASI), and Nail Psoriasi Severity Index (NAPSI).Results: Multivariate analysis of variance was performed between groups. Post hoc analysis underlined the differences between healthy and affected regarding nail plate thickness (0.063±0.011 cm for patients with psoriasis, 0.065±0.014 cm for patients with psoriatic arthritis and 0.051±0.006 cm for healthy controls, p<0.05). Elementary lesions of nail plate and nail bed were compared using Pearson’s chi square test between patients in psoriasis and psoriatic arthritis groups, with no differences except for a trend for onycholisis and crumbling (p=0.07 and 0.06, respectively) in the psoriatic arthritis group. ROC curves were calculated (AUC = 0.68) obtaining also quantitative cut offs for nail plate andnail bed thickness in the affected vs healthy patients.Conclusions: Our study shows that ultrasonography may be a potential advantage in clinical practice. Our results strengthen the information already available in the literature and add quantitative parameters for ultrasonography of the nail.

Abstract:

<p class="abstract"><strong>Background:</strong> <span lang="EN-IN">For a complex chronic disease like psoriasis, having a biomarker to objectively assess the clinical severity can be very helpful in disease management.</span></p><p class="abstract"><strong>Methods:</strong> <span lang="EN-IN">In a hospital based prospective study, 70 patients of psoriasis diagnosed clinically, were studied. The extent of disease severity was assessed using PASI and BSA and patients were grouped into having mild, moderate and severe disease using these scores. Serum high sensitivity </span>C-reactive protein <span lang="EN-IN">(hsCRP) levels were then estimated for each group</span>.<strong></strong></p><p class="abstract"><strong>Results:</strong> <span lang="EN-IN">Of the 70 psoriasis cases enrolled, 46 patients were male and 24 females. Patients with early onset psoriasis were associated with higher values of hsCRP than those with late onset (r=-0.063; p=0.012). A positive correlation was seen between the PASI score and hsCRP levels (r=0.891; p≤0.001). On comparing mean PASI and mean hsCRP in severity groups (mild, moderate and severe), hsCRP was higher in the group with maximum severity (p≤0.001). </span></p><p class="abstract"><strong>Conclusions:</strong> <span lang="EN-IN">A negative correlation between the age of onset and hsCRP implies that, earlier the age of onset, higher is the value of hsCRP. Our study shows a positive correlation between the body surface area and PASI score both of which varied linearly with hsCRP values. The findings also suggest that patients with severe psoriasis have higher mean serum hsCRP levels than patients with mild psoriasiss.</span><span lang="EN-IN">We proposed hsCRP as a useful marker of psoriasis severity that could be used to monitor psoriasis and, together with PASI, as a global index of disease severity.</span></p><p class="abstract"> </p>

Abstract:

<p class="abstract"><strong>Background:</strong> Psoriasis, a chronic skin complication been considered in the recent years by dermatologists as a systemic disease with multi organ abnormalities. Dyslipidemia commonly observed in psoriasis patients may result in cardiovascular complications hence a prompt routine cardiovascular risk evaluation is essential in these patients. A study was designed to assess plasma lipid profile as well as cardiovascular risk markers in psoriasis patients to find out the relationship between cardiovascular risk indicators and psoriasis disease severity.</p><p class="abstract"><strong>Methods:</strong> Study consists of 200 subjects including 100 psoriatics. These psoriatics were sub-grouped based on their increasing PASI score into four groups.<strong></strong></p><p class="abstract"><strong>Results:</strong> The results indicate a significant elevation in lipid parameters and in cadiac risk ratio, atherogenic index of plasma as well as atherogenic coefficient in psoriatics as compared to normal controls. Further a parallel raise has seen in these lipid parameters and risk indicators based on their increasing PASI score.</p><p class="abstract"><strong>Conclusions:</strong> It can be stated from the study results that psoriatics are more affected group for cardiovascular complications and a proper evaluation of cardiovascular risk indicators in these patients is essential in preventing development of cardiovascular risk. Further the risk indicators atherogenic index of plasma and atherogenic coefficient are more promising in evaluating cardiovascular risk in psoriases patients.</p>

Abstract:

Background:Smoking has been associated with psoriasis prevalence and severity.Objective:To evaluate prevalence of smoking in patients with psoriasis and to examine the relationship between smoking and psoriasis severity.Methods:MEDLINE, EMBASE, and Cochrane databases (1960-2012) and conference proceedings (2010-2012) were systematically searched using keywords relevant to psoriasis and smoking. Controlled studies addressing psoriasis and smoking status were included. A meta-analysis for the relative risk of smoking in psoriasis patients was performed.Results:Meta-analysis identified a significant association between smoking and psoriasis with a relative risk of 1.88 (95% CI, 1.66-2.13) for smoking in patients with psoriasis versus patients without psoriasis. Eight articles of 11 with data on smoking and psoriasis severity suggested that severity increases with smoking status.Conclusions:This literature review is in favor of a positive association between the prevalence of smoking and psoriasis as well as an association between smoking and severity of psoriasis.

Abstract:

Background: Previous studies showed conflicting results regarding the mortality risk in psoriasis patients with respect to disease severity and presence of psoriatic arthritis. This study aimed to determine the mortality risk in patients with mild and severe psoriasis and patients with psoriatic arthritis (PsA). Methods: A nationwide population-based cohort study was conducted based on data from the Taiwan National Health Insurance Research Database between 2002 and 2012. Incident psoriasis subjects were classified into two groups: psoriasis without arthritis and psoriasis with arthritis. Patients who had received systemic therapy and/or phototherapy were classified as having severe psoriasis; otherwise, patients were classified as having mild psoriasis. Control subjects without psoriasis were selected to match each psoriasis patient from the database within the same observational period. Cox proportional hazards analysis was used to compare the hazard ratio (HR) of time to death. Results: A total of 106,701 patients with psoriasis were included in this study. After controlling for demographics and comorbidities, psoriasis patients had a higher mortality risk compared with the control group (HR 1.41; 95% confidence interval (CI) 1.36 to 1.46). Compared with psoriasis alone, the mortality risk was not increased for PsA (HR = 1.01; 95% CI 0.93 to 1.10). Besides, severe psoriasis did not increase mortality risk compared with mild psoriasis (HR = 1.0; 95% CI 0.95 to 1.06). Conclusions: Patients with psoriasis had a higher mortality risk compared with control subjects, whereas psoriasis severity and presence of PsA had no impact on mortality risk in psoriasis patients.

Abstract:

Geographic tongue (GT) and fissured tongue (FT) are the more frequent oral lesions in patients with psoriasis. The aims of this study were to compare the prevalence of GT/FT between psoriasis group (PG) and healthy controls (HC) and investigate the correlation between GT/FT and psoriasis severity using the PASI and age of psoriasis onset. Three hundred and forty-eight PG and 348 HC were selected. According to the age of psoriasis onset, the individuals were classified as having early psoriasis and late psoriasis. The severity of vulgaris psoriasis was determined according to PASI. A follow-up was conducted in patients with psoriasis vulgaris (PV) with GT to evaluate the progression of oral and cutaneous lesions. The FT and GT were more frequent in PG than in HC. The incidence of GT was higher in patients with early psoriasis and that of FT in late-psoriasis. There is association between psoriasis intensity and GT; and a higher monthly decrease of PASI score in patients without GT. The presence of GT and FT is higher in PG than in the HC. GT is associated with disease severity and may be a marker of the psoriasis severity.

Abstract:

Psoriasis is a chronic inflammatory systemic disease primarily affecting the skin, but which often involves considerable comorbidities as well. One-third of psoriasis cases start during childhood. In pediatric psoriasis, an association with several medical comorbidities is also indicated. Furthermore, because of its chronic nature and frequent relapses, psoriatic patients tend to require long-term treatment and experience negative impacts on their quality of life. Considering the different clinical characteristics of pediatric psoriasis, it has recently been presented that the pathogenesis of pediatric psoriasis is distinct from adult psoriasis. Treatment for pediatric psoriasis usually involves the same methods as for adults. However, most treatments in pediatric psoriasis are used off-label and research in this regard is still lacking. Targeted therapies involving newly developed biologics are also increasingly being applied to psoriasis in children. This review summarizes the clinical characteristics of pediatric psoriasis and focuses mainly on the updated concepts of pathogenesis and treatments in pediatric psoriasis. This was undertaken to widen the understanding of these relevant aspects and to provide better management of pediatric psoriasis by clinicians.

Abstract:

Background: Psoriasis is a common chronic skin disorder with prevalence of 2.7% in Iraqi community. Psoriasis is a skin disease that it's prevalence affected by many factors which include genetic, environmental, infectious, immunological, biochemical, endocrinological and psychological. Psoriasis is a chronic inflammatory disease with unknown exact pathogenesis, which may be started as skin condition that subsequently associated with systemic complications. The recurrent proliferative inflammatory processes in subject with psoriasis may lead to abnormal lipid metabolism and associated with cardiovascular diseases Aim: This study aims at determining some biochemical parameters of psoriasis . Results: Paraoxonase enzyme which act as antioxidant was significantly decreased in patients with psoriasis as compared to healthy controls. Thus the present study data suggest that PON 1 play an important role in pathogenesis of psoriasis. There was a high significant increase of lipoprotein (a) compared with controls. Lipoprotein (a) may be a risk factor contributing to an increased cardiovascular risk in patients with psoriasis. The frequency of positivity of CRP as inflammatory markers of psoriasis was significantly more in patients with psoriasis as compared to controls. Although, reported studies suggest that increased levels of CRP in psoriasis may be a good assessment of disease severity and prognosis, however, there are some discrepancies in this area. But PASI and CRP are with good predictor of psoriasis severity. A non significant difference in the serum mean of fasting blood level between patients with psoriasis relative to controls. All lipid profiles ( cholesterol, triglyceride, HDL, LDL, VLDL, and NHDL) were significantly higher in psoriasis patients compared to controls. While HDL was significantly lower in patients with psoriasis than in control. In addition, the differences between male psoriasis and male controls were significant. The same pattern was demonstrated for comparison of fem ale psoriasis to female controls.

Abstract:

Although extensively studied, psoriasis still has negative consequences and is associated with multiple comorbidities, including metabolic syndrome. The severity of psoriasis seems to influence the occurrence of diagnostic criteria for metabolic syndrome. 208 patients diagnosed with psoriasis were identified, who were divided into lots depending on the severity of psoriasis, but also to the presence or absence of metabolic syndrome. Interpretation of statistical data was done with SPSS V21 (Statistical Package for Social Science) and MEDCALC (Statistical Software). The coexistence of severe psoriasis with metabolic syndrome increases the risk of developing cardiovascular diseases by 2.97 or greater, with a confidence interval of [1.60, 5.51], than that of patients with severe psoriasis who have no metabolic syndrome. The hypothesis was statistically confirmed by p = 0.003. Analyzing the total group with psoriasis by severity, we found the following distribution: from the total number of 208 patients, 39 (18.8%) had severe psoriasis, 83 (39.9%) moderate psoriasis and 86 (41.3%) mild psoriasis. The higher incidence of metabolic syndrome in patients with psoriasis is evidenced by the Pearson Chi-Square test, where p [0.001. The association of metabolic syndrome in patients with psoriasis is evident. The more severe the psoriasis, the more likely it is to develop metabolic syndrome.

Abstract:

Introduction: Psoriasis is a lifelong autoimmune disease which is characterized by white to red color patches of abnormalskin with patches of itchy and scaly. The term psoriasis derived from Greek word “psora” which means “itch”. It is achronic skin disease, touching about 2% of worldwide population. Different types of psoriasis have been reported such asplaque psoriasis, psoriatic arthritis, scalp psoriasis, flexural (inverse) psoriasis, guttate psoriasis, pustular psoriasis, nailpsoriasis, erythroderma which can be diagnosed by solid conclusion such as skin biopsies etc. Case report: We present thecase of a 55-years-old male with psoriasis. The diagnosis of psoriasis is based on the clinical features and history, as wellas on histopathological examinations of patient's tissue specimens. Any final diagnosis should include a differentialdiagnosis which includes severe seborrheic dermatitis, Contact dermatitis, pityriasisrubrapilaris and mycosis fungoideswhich can be clinically indistinguishable from a severe form of psoriasis. Histopathological studies are also generallyneeded to achieve a definitive diagnosis. After histopathological confirmation of psoriasis methotrexate therapy has beenstarted. Discussion: After comparing this case with several published articles/case reports on psoriasis we found somesimilarity regarding presentation, use and good response to methotrexate therapy but dissimilarity regarding response tosteroid therapy. Conclusion: Our patient showed an excellent response to methotrexate medication Medicine Today 2020 Vol.32(2): 145-147

Abstract:

Psoriasis is a chronic, inflammatory skin disease present in about 3% of the world’s population. The clinical symptoms manifest diversely, therefore one can distinguish several subtypes of psoriasis. The majority of patients with psoriasis experience pruritus, which is an unpleasant sensation that decreases patients’ quality of life. The knowledge on pruritus in different subtypes of psoriasis is limited. We have performed a cross-sectional, prospective, and multicenter study to evaluate the relationship between clinical subtypes of psoriasis (large-plaque, nummular, guttate, palmoplantar, inverse, erythrodermic, palmoplantar pustular, generalized pustular psoriasis, and psoriasis of the scalp) and the prevalence, intensity, and clinical manifestation of itch. We introduced a questionnaire assessing various aspects of pruritus to a total of 254 patients. Out of these, 42 were excluded. Pruritus was present in 92.9% of the remaining patients and its prevalence did not depend on the clinical subtype. A correlation between the severity of psoriasis and the intensity of itch was explicitly noticeable in palmoplantar pustular psoriasis and scalp psoriasis (p < 0.05). The itch sensation was individual and differed among subtypes of psoriasis. In conclusion, pruritus is a frequent phenomenon, and its presentation is different in various subtypes of psoriasis.

Abstract:

BACKGROUND: A number of medications have been reported to induce psoriasis. We report two cases of fluoxetine-related psoriasis and discuss similarities between lithium-, trazodone hydrochloride-, and fluoxetine-induced psoriasis. OBSERVATIONS: Two women being treated for depression with fluoxetine developed psoriasis after 6 and 12 months' exposure. This time frame is clinically similar to that observed with lithium-induced psoriasis. CONCLUSIONS: The occurrence of lithium- and fluoxetine-induced psoriasis may not be random. Both drugs modulate serotonergic function, a factor that may contribute to the pathophysiology of psoriasis. If a patient on acute or long-term fluoxetine therapy develops psoriasis, the drug should be considered as a possible etiologic agent.

Abstract:

Background. Psoriasis is an immune-mediated inflammatory chronic skin disease characterized by chronic inflammation in the dermis, parakeratosis, and excessive epidermal growth. MicroRNAs (miRNAs) are key regulators of immune responses. Although differential expression of miRNAs has been reported in certain inflammatory autoimmune diseases, their role in psoriasis has not been fully illuminated. Our aims were to confirm plasma miRNA expression signatures in psoriasis and to examine their potential influence on psoriasis pathogenesis. Methods. A miRNome PCR array was used to analyse the plasma of psoriasis patients and healthy donors. We performed miRNA pathway enrichment and target gene network analyses on psoriasis plasma samples. Results. We found several specific plasma miRNA signatures relevant to psoriasis. The miRNAs targeted pathways associated with psoriasis, such as the VEGF, MAPK, and WNT signaling pathways. Network analysis revealed pivotal deregulated plasma miRNAs and their relevant target genes and pathways regulating psoriasis pathogenesis. Conclusions. This study analysed the expression of plasma miRNAs and their target pathways, elucidating the pathogenesis of psoriasis; these results may be used to design novel therapeutic strategies and to identify diagnostic biomarkers for psoriasis.

Abstract:

Objective of the Review: to present updated data on psoriasis for clinical pediatricians. Key Points. The article presents updated epidemiological information on psoriasis prevalence in paediatric population; early onset of disease accounts for 70%. Risk factors include genetic predisposition, immune changes, infective agents; children may also have stress as a trigger; in teenagers, smoking can facilitate severe psoriasis. Clinical presentation in paediatric population has some distinctive features: in children, plaque psoriasis is less frequent than in adults. Still, psoriasis of the scalp is diagnosed in approx. 79% of children. Psoriasis therapy in children is limited, but it has much in common with psoriasis management in adults. Conclusion. As psoriasis is associated with multiple non-dermatologic conditions (hepatobiliary disorders, Grohn’s disease, cardiovascular diseases, etc.), early diagnosis facilitates more comprehensive examination of patients for comorbidities and early diagnostics. There are no standardised recommendations for psoriasis management in children. Therefore, paediatric patients require more attention not only from dermatologists, but from paediatricians and multidisciplinary paediatric teams. Keywords: psoriasis, clinical presentations of psoriasis in children.

Abstract:

Background: Psoriasis is a highly visible chronic disease with a substantial impact on quality of life. Objective: The purpose of this review is to understand how psoriasis experience stigmatization. A greater understanding of this may help dermatologists improve treatment strategies for their patients. Methods: A MEDLINE search was performed for the terms stigmatization and psoriasis. Results: Stigmatization is common in psoriasis and has a much greater social and psychological impact than even the extent and severity of skin involvement. Patients with psoriasis may experience stigma in different ways. Psoriasis is more highly stigmatized than most other skin diseases. Lack of knowledge about psoriasis on part of the general public is a significant contributor to how patients with psoriasis are stigmatized by others. Conclusion: Stigma is a significant contributor to negative quality of life in patients with psoriasis. Stigma is an important aspect of disease to consider when formulating optimal psoriasis treatment strategy.

Abstract:

BACKGROUND: Psoriasis vulgaris is a chronic inflammatory skin disorder that can lead to depression. There is a similarity in neurotrophic substance in the pathogenesis of psoriasis and depression; it’s called brain-derived neurotrophic factor (BDNF). BDNF level imbalance potentially affects the severity of psoriasis and depression. AIM: This study aims to know the correlation between serum BDNF level and depression severity in psoriasis vulgaris patient and also the correlation between serum BDNF level and psoriasis vulgaris severity. METHODS: This is an analytical cross-sectional study that 23 psoriasis vulgaris patients participated. All participants have performed serum BDNF level examination with enzyme-linked immunosorbent assay (ELISA). Depression severity assessed with Beck depression inventory-II (BDI-II) and psoriasis severity assessed with psoriasis area and severity index. Correlation between all variables was analysed with Spearman’s correlation test. RESULTS: Serum BDNF level and depression severity are a strongly negative correlation in psoriasis vulgaris patients (r = -0.667 with significant value p = 0.001). There is a moderate negative correlation between serum BDNF level with psoriasis vulgaris severity (r = -0.595 with significant value p = 0.003). CONCLUSION: In psoriasis vulgaris patients, a low level of serum BDNF may increase depression severity and psoriasis vulgaris severity.

Abstract:

Background: Childhood psoriasis affects 2% of the world pediatric population. An association between psoriasis and geographic tongue (GT) in adults has been suggested, but there are no studies in children. Objective: This study aimed to compare the prevalence of oral lesions in pediatric patients with psoriasis (PP) and healthy controls and investigate the correlation between GT, severity, and age of psoriasis onset. Methods: The participants were 17 PP aged <18 years and 91 HC. The severity of vulgaris psoriasis was determined according to Psoriasis Area and Severity Index (PASI) and all patients underwent an oral examination. Results: Oral findings were present in 43% of the participants and the most common lesions were candidiasis and GT. There was a mean earlier onset in psoriasis with GT (3 years old) compared to psoriasis without GT (10 years old). The mean PASI scores in psoriasis with GT and psoriasis without GT were 9 and 3, respectively. Conclusion: Geographic tongue and candidiasis were frequently found in PP. Patients with psoriasis with GT are younger and have earlier onset of the disease, a positive family history of psoriasis, and a severe form of the disease. The present study is the first of its type to demonstrate clinical differences in pediatric PP with and without GT.

Abstract:

Abstract Introduction: Psoriasis is a chronic immune-mediated, genetic disease manifesting in the skin or joints or both. Studies have shown an association between psoriasis and metabolic syndrome [1]. However, there is a scarcity of studies on metabolic and endocrine co-morbidities of hospitalized psoriasis patients. This study aims to compare the prevalence of metabolic and endocrine co-morbidities in hospitalized psoriasis patients to hospitalized non-psoriasis patients. Methods: Data were abstracted from the National Inpatient Sample (NIS) 2016 and 2017 Database. NIS is the largest inpatient hospitalization database in the United States. The NIS was searched for hospitalizations for adult patients aged 18 years or above with a principal or secondary diagnosis of psoriasis and those without any diagnosis of psoriasis. Chi-square test was used to compare the prevalence of common metabolic and endocrine comorbidities between psoriasis and non-psoriasis hospitalized patients. Co-morbidities were obtained from secondary diagnoses. We used ICD-10 codes to obtain psoriasis hospitalizations and co-morbidities. STATA, version 16 was used for analysis. Results: There were over 71 million discharges in the combined 2016 and 2017 NIS database. Out of this, 323,405 hospitalizations had a diagnosis of psoriasis. Psoriasis hospitalizations had a higher prevalence of dyslipidemia (41.8% vs 31.8%, p&lt;0.0001), hypothyroidism (15.6% vs 12.0%, p&lt;0.0001), hyperthyroidism (0.6% vs 0.5%, p=0.0133), type 2 diabetes mellitus (31.1% vs 24.5%, p&lt;0.0001), obesity (24.4% vs 14.3%, p&lt;0.0001), Non-alcoholic fatty liver disease (0.9% vs 0.3%, p&lt;0.0001) and similar prevalence of type 1 diabetes mellitus (0.9% vs 0.9%, p=0.1567) compared to non-psoriasis hospitalizations. Conclusion: Hospitalized psoriasis patients have a higher prevalence of dyslipidemia, hypothyroidism, hyperthyroidism, type 2 diabetes mellitus, obesity and non-alcoholic fatty liver disease compared to non-psoriasis hospitalized patients. Endocrinology consultation during hospitalization will be helpful in managing these comorbidities in psoriasis patients. References 1. Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36(1):21–28. doi:10.1016/j.clindermatol.2017.09.005

Abstract:

Background:Psoriasis is an important feature of psoriatic arthritis (PsA). Psoriasis itself is known to have a significant impact on Health-related Quality of life (HRQoL)1, however its role within PsA is less well understood. In daily practice, assessment of psoriasis may not always be a priority for rheumatologists, having been trained to focus on articular involvement. In order to assess whether psoriasis deserves more attention from rheumatologists, the aim of this study is to evaluate the influence of psoriasis on HRQoL in early PsA patients.Objectives:To describe the evolution of psoriasis severity during the first year of follow up in patients with early PsA and to evaluate the impact of psoriasis severity on HRQoL.Methods:Real world data were used from the Dutch south west Psoriatic Arthritis cohort (DEPAR) study, consisting of newly diagnosed PsA patients included between July 2013 and February 2019. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI) and categorized in: no psoriasis (PASI 0), mild psoriasis (PASI<7), moderate psoriasis (PASI 7-12) and severe psoriasis (PASI>12). Musculoskeletal disease severity was measured with the Disease Activity in PSoriatic Arthritis (DAPSA) score as contrast for psoriasis severity. DAPSA was categorized in: remission (REM[DAPSA≤4]), low disease activity (LDA[DAPSA≤14]), moderate disease activity (MDA[DAPSA≤28]) and high disease activity (HDA[DAPSA>28]).2General HRQoL was assesed with the Short-Form 36 (SF-36[Physical component scale and Mental component scale]). Skin-specific HRQoL was measured with the Skindex-17 (psychosocial scale and symptoms scale).Results:In total, 435 patients were included. Mean (sd) age was 49.7 (13.4) years and 53% (n=229) was male. Psoriasis severity does not fluctuate much over the course of the first year and the majority of patients had mild psoriasis (Figure 1). HRQoL worsened with increasing psoriasis severity, when measured by the Skindex17. This reduction in HRQoL was not seen when measured with the SF-36 (Figure 2).Figure 1.Psoriasis severity categories during the first year of follow up. No psoriasis (PASI 0), mild psoriasis (PASI<7), moderate psoriasis (PASI 7-12) and severe psoriasis (PASI>12).Figure 2.A, B: Median Skindex17 psychosocial score and symptoms score per psoriasis severity category and DAPSA category at baseline. C,D: Mean SF36 Physical component scale (PCS) score and Mental component scale (MCS) score per psoriasis severity category and DAPSA category at baseline. No psoriasis (PASI 0), mild psoriasis (PASI<7), moderate psoriasis (PASI 7-12) and severe psoriasis (PASI>12). REM (DAPSA<4), LDA (DAPSA<14), MDA (DAPSA<28) and HDA (DAPSA>28)Conclusion:In early PsA patients, psoriasis severity is mostly mild, but considerably impacts HRQoL when measured using a skin specific questionnaire. For optimal management of PsA patients, we therefore recommend rheumatologists to additionally acquire information on the degree of psoriatic involvement. In our opinion, this information is valuable for the adequate assessment of HRQoL.References:[1]Strober B, Greenberg JD, Karki C, Mason M, Guo N, Hur P, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9(4):e027535.[2]Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811-8.Disclosure of Interests:Fazira R. Kasiem: None declared, Marc R Kok Grant/research support from: BMS and Novartis, Consultant of: Novartis and Galapagos, Ilja Tchetverikov: None declared, Kim Wervers: None declared, Johanna Hazes: None declared, Jolanda Luime: None declared, Marijn Vis Grant/research support from: Novartis, Pfizer – grant/research support, Consultant of: AbbVie, Celgene Corporation, Eli Lilly, Novartis, Pfizer – consultant

Abstract:

Recent genome-wide association studies (GWAS) have identified multiple genetic risk factors for psoriasis, but data on their association with age of onset have been marginally explored. The goal of this study was to evaluate known risk alleles of psoriasis for association with age of psoriasis onset in three well-defined case-only cohorts totaling 1,498 psoriasis patients. We selected 39 genetic variants from psoriasis GWAS and tested these variants for association with age of psoriasis onset in a meta-analysis. We found that rs10484554 and rs12191877 near HLA-C and rs17716942 near IFIH1 were associated with age of psoriasis onset with false discovery rate < 0.05. The association between rs17716942 and age of onset was not replicated in a fourth independent cohort of 489 patients (). The imputed HLA-C*06:02 allele demonstrated a much stronger association with age of psoriasis onset than rs10484554 and rs12191877. We conclude that despite the discovery of numerous psoriasis risk alleles, HLA-C*06:02 still plays the most important role in determining the age of onset of psoriasis. Larger studies are needed to evaluate the contribution of other risk alleles, including IFIH1, to age of psoriasis onset.

Abstract:

In a three year period, authors observed 16 cases whith plaque psoriasis accompanied with nail symptoms characteristic for typical psoriasis. Microscopy examinations were positive in cases of 7 in fingernails, and in 3 cases of toe nails. In cultures, pathogenic agents were grown in 4 cases from finger nails, in 2 cases from toe nails. Considering the 16 psoriasis cases out of the 1087 mycotic tests carried out in the 3 years period, onychomycosis occurred only in 1,5% of the cases. Therefore further studies are needed for the assessment of onychomycosis in psoriatic cases.

Abstract:

BackgroundWide-ranging psoriasis prevalence estimates have been reported, possibly due to methodological differences.ObjectivesTo assess the prevalence of psoriasis in Denmark and to validate the use of questionnaire-based data to identify patients with psoriasis.MethodsWe used data from the Danish Skin Cohort, a prospective cohort comprising general population adults, as well as patients with dermatologist-verified psoriasis and atopic dermatitis, respectively. The general population cohort was interviewed to assess the psoriasis prevalence in Denmark, and validation of the questions was performed.ResultsFrom 3490 general population participants, 7.9% (n=275) were found to have self-reported psoriasis. Of these, 221 (prevalence 6.3%) had their disease diagnosed by a physician (the dermatologist-diagnosed prevalence was 4.3%), whereas 54 (prevalence 1.6%) were not diagnosed by a physician. A total of 176 (5%) had active psoriasis within the last 12 months. More than half of patients had at least one disease flare in the last 12 months, and 44.4% of patients with psoriasis had at least one family member with psoriasis, whereas this was only the case for 13.7% of non-psoriasis individuals. Validation of the psoriasis diagnosis yielded a high sensitivity and specificity, with little incremental value of limiting diagnoses to those diagnosed by a physician.ConclusionThe lifetime-prevalence of self-reported psoriasis was found to be 7.9%, whereas the 1-year prevalence (ie, currently active psoriasis) was 5.0%. If used appropriately, questionnaire-based data may accurately identify patients with psoriasis.